Comparative Study Between Nicorandil and Nifedipine for the Treatment of Preterm Labour
Primary Purpose
Preterm Labor With Preterm Delivery
Status
Unknown status
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
Potassium Channel Opener
Calcium channel blocker
Sponsored by
About this trial
This is an interventional prevention trial for Preterm Labor With Preterm Delivery
Eligibility Criteria
Inclusion Criteria:
- BMI between (20 - 30 kg /m²).
- pregnant female with single viable fetus who presented to the outpatient clinic or Emergency room with the criteria of diagnosis of preterm labor between 28 and before completing 34 weeks pregnancy
Exclusion Criteria:
- - Any condition in which continuation of pregnancy will jeopardize maternal or fetal welfare.
- Cervix dilatation greater than 4 cm.
- Polyhydramnios [amniotic fluid index (AFI) greater than 24 cm or deep vertical pocket more than 8 cm.]
- Oligohydramnios (AFI less than 5 cm).
Suspected intrauterine infection if Maternal fever is present as a constant feature plus one or more of the following:-
- Maternal leucocytosis (more than 15,000)
- purulent vaginal discharge
- Fetal tachycardia more than 180 bpm.
- Growth restriction.
- Major antepartum hemorrhage
- Major maternal medical disorders such as diabetes, hypertension, systemic lupus,liver and kidney dysfunction .
- Multiple gestation pregnancy.
- Signs of fetal non reassuring CTG
- Signs of fetal abnormal CTG
- Lethal fetal anomaly incompatible with life.
Premature Rupture of membrane.
--Contraindication for the use of Nifedipine and/or Nicorandil such as drug allergy, cardiac disease, liver disease and kidney disease
- previous caesarean section
Sites / Locations
- Manella Fayez Zaki BesharaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
group Nicorandil
group Nifedipine
Arm Description
women will receive oral Nicorandil 20 mg initially followed by 10 mg at 8 hourly intervals for 48 hours
Women will receive oral Nifedipine loading dose 20 mg orally followed by 10 mg every 8 hours for 48 hours
Outcomes
Primary Outcome Measures
Number of participants with successful prolongation of pregnancy for a period of 48 hours following administration of the studied drug.
By follow up of the patients labor progress by the investigator through vaginal examination of the cervical dilatation
Secondary Outcome Measures
assess safety of the drug on fetal outcome
By recording the ABGAR score at 1 and 5 minutes after Birth
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04846621
Brief Title
Comparative Study Between Nicorandil and Nifedipine for the Treatment of Preterm Labour
Official Title
Comparative Study Between Nicorandil and Nifedipine for the Treatment of Patients Presenting by Preterm Labor
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2020 (Actual)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
July 1, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Nicorandil (potassium channel activator) is claimed to be as effective as Nifedipine (calcium channel blocker) for tocolysis in preterm labour
aim of the study: To assess the efficacy of Nicorandil compared with Nifedipine as a tocolytic agent in delaying labour for 48 hours following their administration
Detailed Description
Preterm labour refers to a delivery that occurs between 20 weeks and before completing 37 weeks of gestation. It may or may not be preceded by preterm labor Preterm labor (PTL) is one of the leading causes of perinatal morbidity and mortality. It is one of the major public health problems, especially with reference to mortality, disability and health care expenses
The diagnosis of preterm labor based upon clinical criteria of regular painful uterine contractions occurs between 20 weeks and before 37 weeks gestation accompanied by cervical change (dilation and/or effacement). Vaginal bleeding and/or ruptured membranes in this setting increase diagnostic certainty , using the following specific criteria:
Uterine contractions (≥4 every 20 minutes or ≥8 in 60 minutes) Plus one of the following:-
Cervical dilation equal or more than 3 cm
Cervical length less than 20 mm on transvaginal ultrasound
Cervical length between 20 to less than 30 mm on transvaginal ultrasound and positive fetal fibronectin test . (This criterion will not be relied upon in this study because it is costly and widely not available in most laboratories)
Since uterine contractions are the most frequently recognized sign of preterm labor, inhibition of uterine contractions with tocolytic agents to prolong pregnancy and reduce neonatal complications has been and continues to be the focus of treatment of preterm labor
• Nifedipine, a calcium channel blocker, could be used as a first line tocolytic agent
Owing to this side effects of Nifedipine, another novel drug (Nicorandil) is studied and according to literature Nicorandil is as effective as Nifedipine for tocolysis in preterm labour
is an anti-angina medication that has the dual properties of a nitrate and ATP-sensitive K+ channel activator. Nicorandil has proved to be safe as anti angina treatement in pergnency
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm Labor With Preterm Delivery
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
all cases in both groups will not know which drug they receive
Allocation
Randomized
Enrollment
230 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
group Nicorandil
Arm Type
Other
Arm Description
women will receive oral Nicorandil 20 mg initially followed by 10 mg at 8 hourly intervals for 48 hours
Arm Title
group Nifedipine
Arm Type
Other
Arm Description
Women will receive oral Nifedipine loading dose 20 mg orally followed by 10 mg every 8 hours for 48 hours
Intervention Type
Drug
Intervention Name(s)
Potassium Channel Opener
Intervention Description
Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
Intervention Type
Drug
Intervention Name(s)
Calcium channel blocker
Intervention Description
Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
Primary Outcome Measure Information:
Title
Number of participants with successful prolongation of pregnancy for a period of 48 hours following administration of the studied drug.
Description
By follow up of the patients labor progress by the investigator through vaginal examination of the cervical dilatation
Time Frame
48 hours prolongation of pregnancy after starting the studied drug
Secondary Outcome Measure Information:
Title
assess safety of the drug on fetal outcome
Description
By recording the ABGAR score at 1 and 5 minutes after Birth
Time Frame
5 minutes
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
BMI between (20 - 30 kg /m²).
pregnant female with single viable fetus who presented to the outpatient clinic or Emergency room with the criteria of diagnosis of preterm labor between 28 and before completing 34 weeks pregnancy
Exclusion Criteria:
- Any condition in which continuation of pregnancy will jeopardize maternal or fetal welfare.
Cervix dilatation greater than 4 cm.
Polyhydramnios [amniotic fluid index (AFI) greater than 24 cm or deep vertical pocket more than 8 cm.]
Oligohydramnios (AFI less than 5 cm).
Suspected intrauterine infection if Maternal fever is present as a constant feature plus one or more of the following:-
Maternal leucocytosis (more than 15,000)
purulent vaginal discharge
Fetal tachycardia more than 180 bpm.
Growth restriction.
Major antepartum hemorrhage
Major maternal medical disorders such as diabetes, hypertension, systemic lupus,liver and kidney dysfunction .
Multiple gestation pregnancy.
Signs of fetal non reassuring CTG
Signs of fetal abnormal CTG
Lethal fetal anomaly incompatible with life.
Premature Rupture of membrane.
--Contraindication for the use of Nifedipine and/or Nicorandil such as drug allergy, cardiac disease, liver disease and kidney disease
previous caesarean section
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
manella beshara, master
Phone
01271750936
Email
michael.leuis89@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
manella beshara, master
Organizational Affiliation
Ain Shams University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Manella Fayez Zaki Beshara
City
Egypt
State/Province
Alexandria
ZIP/Postal Code
21500
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
manella beshara, master
Phone
01271750936
Email
michael.leuis89@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Time Frame
in about 3 months
Citations:
PubMed Identifier
35947046
Citation
Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2.
Results Reference
derived
Learn more about this trial
Comparative Study Between Nicorandil and Nifedipine for the Treatment of Preterm Labour
We'll reach out to this number within 24 hrs